In his latest article for FT Money, Terry Smith believes that AstraZeneca’s problems go much deeper than its recent setback for a single drug.
In his latest article for FT Money, Terry Smith discusses the unique advantage investing in equities has over other asset classes.
In his latest article and podcast for FT Money, Terry Smith discusses why it may seem a strange position for an active fund manager to adopt but he is in favour of passive or index investment; the problems with emerging market ETFs; and the types of companies that these ETFs invest in.
Terry Smith discusses 'known knowns' and looks at what investors should focus on.
Terry Smith discusses the 'Nifty Fifty' and what it can tell us about bond proxies.
Terry Smith discusses Fundsmith’s investment strategy and why investors should not write off bond-proxies just yet.
Investors should “buy, forget and enjoy the results”. Terry Smith gives his views on how to achieve a superior investment performance in 2016 in a feature article by FT Money editor Claer Barrett.
Terry Smith reflects on five successful years of Fundsmith and discusses what he has learnt over this time, including the importance of sticking to the facts and why selling good companies is rarely a good move
Terry Smith reflects on the fifth anniversary of the Fundsmith Equity Fund and explains why investing in high-quality assets is so important when it comes to attaining long-term outperformance.
Terry Smith analyses the pharmaceutical industry, concluding that many companies are flattering their true performance by encouraging the market to focus on 'underlying' earnings that do not reflect reality.